Developer docs
API playgroundTry for free, no card

Search company profiles

Acticor Biotech

Full company profile

uuid00027ah

Namestring
Acticor Biotech
Legal namestring
Acticor Biotech
Company typeenum
Private
Founded yearint
2010
Short descriptiontext

Acticor Biotech is a Paris-based, clinical-stage biopharmaceutical company developing glenzocimab, a single proprietary drug candidate for the treatment of acute ischemic stroke, sustained pre-revenue by repeated private capital raises and awaiting further financing and regulatory milestones.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
stroke therapeutics, acute ischemic stroke, biopharmaceutical drug development, monoclonal antibody therapy, thrombus inhibition
Industry2 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Acute Stroke Therapeutics
Social media profiles2 records
Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue biopharmaceutical company developing glenzocimab for stroke treatment. Revenue generation expected through future drug commercialization or licensing agreements upon regulatory approval.

businesswire.com
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Acticor Biotech is developing glenzocimab, a clinical-stage monoclonal antibody fragment drug candidate for the acute-phase treatment of acute ischemic stroke. The company operates as a clinical-stage biopharmaceutical R&D organization pursuing regulatory validation of a single proprietary asset targeting an underserved therapeutic area.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Glenzocimab
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Peers10 records
1Athersys
TypeEmerging player
Description

Developed MultiStem cell therapy for ischemic stroke (MASTERS-2 program); directly comparable clinical-stage biotech targeting the same acute ischemic stroke population.

TypeEmerging player
Description

Clinical-stage biotech developing 3K3A-APC for acute ischemic stroke; directly comparable single-asset, neuro-protection-oriented developer focused on the same indication.

TypeBroad incumbent
Description

Developer of caplacizumab (nanobody/antibody-fragment) for acquired TTP; Sanofi's nano-body franchise represents the closest antibody-fragment platform comparable to glenzocimab.

TypeEmerging player
Description

Developed CTX cell therapy for stroke disability; comparable UK-listed clinical-stage biotech addressing post-stroke neurology outcomes.

5Boehringer Ingelheim
TypeBroad incumbent
Description

Markets Actilyse (alteplase) and has developed tenecteplase for acute ischemic stroke; large incumbent with overlapping stroke-treatment indication and post-stroke biologics expertise.

TypeBroad incumbent
Description

Large neurology-focused biopharmaceutical incumbent with biologics expertise across neurovascular/neurodegenerative indications; comparable strategic-acquirer profile for late-stage stroke assets.

TypeEmerging player
Description

Developing DM199 (klotho-based biologic) for acute ischemic stroke; emerging clinical-stage peer with overlapping neurovascular therapeutic development.

TypeDirect peer
Description

Clinical-stage complement-inhibitor biotech whose mechanism-based neurovascular approach is conceptually analogous to glenzocimab's targeted biological intervention; serves as a directly comparable emerging player.

TypeBroad incumbent
Description

Developer of Activase (alteplase), the established intravenous thrombolytic standard of care for acute ischemic stroke; broad incumbent neurology/biologics portfolio with overlapping indication.

TypeEmerging player
Description

European clinical-stage biotech developing Spiegelmer-based biologics; comparable small-cap, single-asset European biotech with similar pre-revenue clinical profile.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acticor Biotech

Acute Stroke Therapeuticsacticor-biotech.com

Acticor Biotech is a Paris-based, clinical-stage biopharmaceutical company developing glenzocimab, a single proprietary drug candidate for the treatment of acute ischemic stroke, sustained pre-revenue by repeated private capital raises and awaiting further financing and regulatory milestones.

Acticor Biotech firmographics

Firmographics
Name
Acticor Biotech
Legal name
Acticor Biotech
Website
https://acticor-biotech.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Acticor Biotech is a Paris-based, clinical-stage biopharmaceutical company developing glenzocimab, a single proprietary drug candidate for the treatment of acute ischemic stroke, sustained pre-revenue by repeated private capital raises and awaiting further financing and regulatory milestones.
Ownership category
akta.pro rank

Acticor Biotech industry classification

Industry
Product category
Acute Stroke Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals

Keywords

  • Stroke therapeutics
  • Acute ischemic stroke
  • Biopharmaceutical drug development
  • Monoclonal antibody therapy
  • Thrombus inhibition

Where Acticor Biotech is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Markets served

Acticor Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Drug Development and Commercialization: Pre-revenue biopharmaceutical company developing glenzocimab for stroke treatment. Revenue generation expected through future drug commercialization or licensing agreements upon regulatory approval.

Acticor Biotech product offering

Product offering

Core offering

Acticor Biotech is developing glenzocimab, a clinical-stage monoclonal antibody fragment drug candidate for the acute-phase treatment of acute ischemic stroke. The company operates as a clinical-stage biopharmaceutical R&D organization pursuing regulatory validation of a single proprietary asset targeting an underserved therapeutic area.

Differentiator

Problem solved

Functional benefit

Products and services

  • Glenzocimab

Companies that use Acticor Biotech

Customer profile

Segments1 record

Ideal customer profiles1 record

Acticor Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Acticor Biotech partnerships and signals

Strategic signal

Scale indicators2 records

Acticor Biotech competitors and assessment

Company assessment

Emerging players

  • Athersys: Developed MultiStem cell therapy for ischemic stroke (MASTERS-2 program); directly comparable clinical-stage biotech targeting the same acute ischemic stroke population.
  • ZZ Biotech: Clinical-stage biotech developing 3K3A-APC for acute ischemic stroke; directly comparable single-asset, neuro-protection-oriented developer focused on the same indication.
  • ReNeuron Group: Developed CTX cell therapy for stroke disability; comparable UK-listed clinical-stage biotech addressing post-stroke neurology outcomes.
  • DiaMedica Therapeutics: Developing DM199 (klotho-based biologic) for acute ischemic stroke; emerging clinical-stage peer with overlapping neurovascular therapeutic development.
  • Noxxon Pharma: European clinical-stage biotech developing Spiegelmer-based biologics; comparable small-cap, single-asset European biotech with similar pre-revenue clinical profile.

Broad incumbents

  • Ablynx (Sanofi): Developer of caplacizumab (nanobody/antibody-fragment) for acquired TTP; Sanofi's nano-body franchise represents the closest antibody-fragment platform comparable to glenzocimab.
  • Boehringer Ingelheim: Markets Actilyse (alteplase) and has developed tenecteplase for acute ischemic stroke; large incumbent with overlapping stroke-treatment indication and post-stroke biologics expertise.
  • Biogen: Large neurology-focused biopharmaceutical incumbent with biologics expertise across neurovascular/neurodegenerative indications; comparable strategic-acquirer profile for late-stage stroke assets.
  • Genentech (Roche): Developer of Activase (alteplase), the established intravenous thrombolytic standard of care for acute ischemic stroke; broad incumbent neurology/biologics portfolio with overlapping indication.

Direct peers

  • Annexon, Inc. Clinical-stage complement-inhibitor biotech whose mechanism-based neurovascular approach is conceptually analogous to glenzocimab's targeted biological intervention; serves as a directly comparable emerging player.

Market position

Customer concentration

Acticor Biotech social profiles

Digital presence

Acticor Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acticor Biotech leadership team

Management profile

Number of profiles

Profiles5 records

Acticor Biotech funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acticor Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acticor Biotech

What does Acticor Biotech do?

Acticor Biotech is developing glenzocimab, a clinical-stage monoclonal antibody fragment drug candidate for the acute-phase treatment of acute ischemic stroke. The company operates as a clinical-stage biopharmaceutical R&D organization pursuing regulatory validation of a single proprietary asset targeting an underserved therapeutic area.

Is Acticor Biotech a public or private company?

Acticor Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Acticor Biotech founded?

Acticor Biotech was founded in 2010. It employs 11 to 50 people.

Where is Acticor Biotech based?

Acticor Biotech is headquartered in Paris, France, in the Europe region.

How does Acticor Biotech make money?

One revenue line is on record: drug Development and Commercialization.

Who are Acticor Biotech's main competitors?

Emerging players on record are Athersys, ZZ Biotech, ReNeuron Group, DiaMedica Therapeutics and Noxxon Pharma. Broad incumbents are Ablynx (Sanofi), Boehringer Ingelheim, Biogen and Genentech (Roche). Annexon, Inc. is listed as a direct peer.

Does Acticor Biotech have an API?

No public API is recorded for Acticor Biotech.

What industry is Acticor Biotech in?

Acticor Biotech's product category is Acute Stroke Therapeutics. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAcute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsightDelveInsight published a market research report forecasting expansion in the acute ischemic stroke treatment market from 2026 to 2036, driven by increased disease awareness and a robust pipeline of innovative therapies. The report highlights key clinical developments for drugs such as glenzocimab by Acticor Biotech, milvexian by Bristol Myers Squibb and Janssen Pharmaceuticals, and LT3001 by Lumosa Therapeutics across the seven major markets. These emerging treatments are anticipated to reshape the current landscape dominated by standard care options like aspirin and alteplase.YahooActicor Biotech Launches a Call for Tenders to Provide a Continuation or Sale Plan as Part of the Receivership ProcedureActicor Biotech launched a call for tenders for a restructuring or sale plan as part of its receivership proceedings, with responses due October 15, 2024. The Paris Commercial Court opened receivership on August 6, 2024, and will rule on extension on October 3, 2024. The company's AGM is set for October 25, 2024.Business Wire BlogActicor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of May 31, 2024Acticor Biotech disclosed its total voting rights and shares as of May 31, 2024, listing 15,755,227 shares with 15,537,023 voting rights. The company is developing glenzocimab for cardiovascular emergencies, with ongoing clinical trials including a futility analysis expected in Q4 2024.GlobeNewswireActicor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergenciesActicor Biotech updated its glenzocimab development plan after ACTISAVE phase 2/3 results, citing positive trends in subpopulations. The company will continue trials, including GREEN and GALICE in stroke and LIBERATE in myocardial infarction, with interim futility analysis expected in Q4 2024.Business Wire BlogACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023ACTICOR BIOTECH postponed publication of its 2023 annual results and universal registration document, originally due April 30, 2024, to account for the ACTISAVE phase 2/3 trial results. The company can finance operations until October 2024. The new publication date will be announced in a press release.MarketScreenerActicor Biotech: falls after capital increaseActicor Biotech shares fell 22% following the completion of an eight million euro capital increase issued at 3.13 euros per share. The company intends to use the proceeds to fund its stroke treatment development plan, specifically the phase 2/3 ACTISAVE study. These funds are estimated to cover operational costs until October 2024.Business Wire BlogActicor Biotech Completes a Capital Increase for a Total Gross Amount of 8 Million EurosActicor Biotech completed a capital increase raising 8 million euros through the issuance of new shares at €3.13 each. The company intends to use these funds to finalize Phase 2/3 trials for its stroke drug glenzocimab and validate registration plans with regulatory authorities in Europe and the United States.GlobeNewswireThe University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attackThe University of Birmingham and Acticor Biotech announced the first patient treated in the LIBERATE clinical trial evaluating glenzocimab for heart attacks. The randomized, double-blind Phase 2b trial will enroll over 200 STEMI patients, with results expected by Q4 2025.Investing.comActicor Biotech reports stroke drug safety and mortality reduction By Investing.comActicor Biotech published phase 1b/2a ACTIMIS study results in The Lancet Neurology, showing glenzocimab with standard thrombolysis reduced symptomatic intracranial hemorrhage to 0% from 10% and all-cause mortality to 8% from 21% in acute ischemic stroke patients. The company is now focusing on the ACTISAVE phase 2/3 trial, with results expected in Q2 2024.GlobeNewswireActicor Biotech has just and timely completed patient recruitment of its phase 2/3 study in strokeActicor Biotech completed enrollment of 438 stroke patients in its ACTISAVE phase 2/3 trial, with results expected in Q2 2024. The study evaluates glenzocimab for acute ischemic stroke, and the company plans to consult regulators in 2024 to confirm Phase 3 design for registration by 2028.